The earnings call highlighted significant improvements in cost reduction and financial metrics, along with successful product launches. However, challenges remain with lowered revenue guidance in the biosecurity segment and ongoing operating losses. The company is strategically positioned for future growth, especially in automation and life science tools.

Company Guidance -

Q3 2025

During the recent call, Ginkgo Bioworks provided guidance on their financial and operational strategy. The company is targeting adjusted EBITDA breakeven by the end of 2026 and has achieved a $250 million annual run rate cost savings, reaching this goal a quarter early. They reported $474 million in cash and cash equivalents with no bank debt, emphasizing a strong cash position as a margin of safety. In Q2 2025, Ginkgo's Cell Engineering revenue increased by 8% year-over-year to $39 million, while Biosecurity generated $10 million in revenue at an 18% segment gross margin. The company also reported a significant reduction in Cell Engineering R&D and G&A expenses by 63% and 57%, respectively, compared to Q2 2024. Adjusted EBITDA improved to negative $28 million from negative $99 million in Q2 2024, and cash burn decreased to $38 million. Ginkgo reaffirmed its 2025 revenue guidance of $167 million to $187 million, with Cell Engineering expected to contribute $117 million to $137 million and Biosecurity at least $40 million. The company is focusing on expanding its life science tools business, leveraging automation, data points, and new reagent products to drive growth into 2026.

Cost Reduction Achievements

Achieved a $250 million annual run rate cost savings a quarter early, which was strategically important for maintaining a cash margin of safety with $474 million in cash and no bank debt.

Improvement in Financial Metrics

Adjusted EBITDA improved from negative $99 million in Q2 2024 to negative $28 million in Q2 2025, a 72% improvement. Cash burn decreased from $110 million in Q2 2024 to $38 million in Q2 2025.

Launch of New Reagent Product

Launched a cell-free protein synthesis reagent with twice the yields for half the cost compared to market leaders, priced at $2,000 for a 10 ml kit.

Ginkgo Bioworks Holdings (DNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-1.41 / -	-1.08	―	―	―
Aug 07, 2025	2025 (Q2)	-1.57 / -1.10	-4.4	75.00% (+3.30)
May 06, 2025	2025 (Q1)	-1.53 / -1.68	-3.2	47.50% (+1.52)
Feb 25, 2025	2024 (Q4)	-1.50 / -2.00	-4.4	54.55% (+2.40)
Nov 12, 2024	2024 (Q3)	-2.73 / -1.08	-6.4	83.13% (+5.32)
Aug 08, 2024	2024 (Q2)	-3.10 / -4.40	-3.6	-22.22% (-0.80)
May 09, 2024	2024 (Q1)	-3.33 / -3.20	-4.4	27.27% (+1.20)
Feb 29, 2024	2023 (Q4)	-3.87 / -4.40	-4	-10.00% (-0.40)
Nov 08, 2023	2023 (Q3)	-3.66 / -6.40	-16.4	60.98% (+10.00)
Aug 09, 2023	2023 (Q2)	-3.45 / -3.60	-16.4	78.05% (+12.80)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$13.46	$12.29	-8.69%
May 06, 2025	$6.45	$7.40	+14.73%
Feb 25, 2025	$10.29	$9.11	-11.47%
Nov 12, 2024	$8.39	$8.60	+2.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.